Clozapine REMS: ANC-based continuation and interruption guidance for standard and benign ethnic neutropenia pathways.
REMS Recommendation
General population pathway: ANC is in the continuation range.
Verified
Last Review: 2026-07-17
| ≥ 1500 /µL | Continue treatment |
| 1000–1499 /µL (Mild) | Continue treatment; monitor 3x weekly |
| 500–999 /µL (Moderate) | Interrupt treatment; daily monitoring |
| < 500 /µL (Severe) | Discontinue treatment; urgent hematology referral |
FDA. • U.S. Food and Drug Administration.. 2021;Current mandatory REMS oversight program for clozapine-induced neutropenia. All prescribers, pharmacies, and patients must be enrolled.
Kane JM et al. • Arch Gen Psychiatry.. 1988;45(9):789-96. The landmark study establishing clozapine efficacy in treatment-resistant schizophrenia (30% response rate vs 4% for chlorpromazine).
Last Comprehensive Review: 2026-07-17
Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
